Michael Yu

Partner at Cooley

Speaker

Michael Yu is the partner in charge of Cooley's Shanghai office. His practice focuses on initial public offerings and other equity capital markets transactions on the Hong Kong Stock Exchange, pre-IPO investments, public takeovers and listing rules and securities regulations compliance.

Michael has actively participated in the strategic initiative by HKEX to attract new-economy companies to list in Hong Kong. In particular, he advised Asymchem on its US$979 million IPO and listing on HKEX which is the largest healthcare HK IPO in 2021. He has also advised Ascletis Pharma on its US$400 million HK IPO in 2018, the first pre-revenue biotech IPO on HKEX under its new listing regime for companies from emerging and innovative sectors. He has also advised a number of new-economy companies, including companies in biotech and internet sectors, on their HK IPOs.

Michael was recognized in IFLR1000 2019 and 2021 as a Notable Practitioner for equity capital markets work.